Fox Rothschild's Marc Wagner on why domestic manufacturing reduces drug shortage risk — and why FDA inspection efficiency is as important as supply chain resilience.
|Videos|July 27, 2021
Pharmaceutical CEO Leadership: Collaboration in Pharma – Innovation
In this segment, members of the Pharmaceutical CEO Leadership: Collaboration in Pharma panel talk about the need to think outside the box when it comes to partnering, for example, by expanding relationships with technology, data science, and logistics companies. The challenges of protecting intellectual property are also discussed, as are the effects innovation can have on pricing and access.
Advertisement
Advertisement
Related to this article
Fox Rothschild's Marc Wagner on how 503A pharmacies and 503B outsourcing facilities fill drug supply gaps — from COVID injectables to GLP-1s.
Fox Rothschild's Marc Wagner on why scaling drug production is so slow — overseas API sourcing, supplier qualification, and FDA site approvals that take years.
Waiting for perfect data before deploying AI is a trap — and why 60-70% accuracy is often good enough to start.
Fox Rothschild's Marc Wagner on why the FDA counts 70 drugs in shortage while ASHP counts 188 — and what's driving the gap.
Pharma's chain of custody model is migrating into food and consumer goods — and becoming a cross-industry differentiator.
Pharma logistics are overqualified by design — and how agentic AI can now optimize across thousands of lanes in days, not months.
Pharma AI adoption fails not because of the technology — but because organizations deploy tools before they're ready to use them.
Advertisement
Advertisement
Trending on PharmExec
1
AstraZeneca Taps insitro AI for MASH in Deal Worth Up to $1.5 Billion
2
The Impact That the Renewed Focus on Domestic Manufacturing Might Have on the Supply Chain
3
FDA Launches Rare Disease Framework Initiative
4
Pharmaceutical Executive Daily: Gilead Enters $1.87 Billion Collaboration and License Agreement with Vir Biotechnology
5